JP2017516784A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017516784A5 JP2017516784A5 JP2016569606A JP2016569606A JP2017516784A5 JP 2017516784 A5 JP2017516784 A5 JP 2017516784A5 JP 2016569606 A JP2016569606 A JP 2016569606A JP 2016569606 A JP2016569606 A JP 2016569606A JP 2017516784 A5 JP2017516784 A5 JP 2017516784A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- cancer
- pharmaceutically acceptable
- acceptable salt
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462003798P | 2014-05-28 | 2014-05-28 | |
| US62/003,798 | 2014-05-28 | ||
| US201462088200P | 2014-12-05 | 2014-12-05 | |
| US62/088,200 | 2014-12-05 | ||
| PCT/US2015/032990 WO2015184145A1 (en) | 2014-05-28 | 2015-05-28 | Use of eribulin and poly (adp ribose) polymerase (parp) inhibitors as combination therapy for the treatment of cancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017516784A JP2017516784A (ja) | 2017-06-22 |
| JP2017516784A5 true JP2017516784A5 (enExample) | 2018-07-05 |
| JP6648040B2 JP6648040B2 (ja) | 2020-02-14 |
Family
ID=54699806
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016569606A Active JP6648040B2 (ja) | 2014-05-28 | 2015-05-28 | がん治療のための併用療法としてのエリブリン及びポリ（ａｄｐリボース）ポリメラーゼ（ｐａｒｐ）阻害剤の使用 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US10238630B2 (enExample) |
| EP (1) | EP3148336B1 (enExample) |
| JP (1) | JP6648040B2 (enExample) |
| WO (1) | WO2015184145A1 (enExample) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101434673B1 (ko) | 2004-06-03 | 2014-08-26 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 할리콘드린 ｂ 유사체의 제조를 위한 중간체 |
| PE20120923A1 (es) | 2009-03-30 | 2012-08-27 | Eisai Randd Man Co Ltd | Composiciones farmaceuticas comprendiendo liposomas que contiene eribulina o una sal del mismo |
| CN105338977B (zh) | 2013-06-26 | 2018-10-16 | 卫材R&D管理有限公司 | 艾日布林和乐伐替尼作为治疗癌症的联合疗法的用途 |
| ITUB20159206A1 (it) * | 2015-12-22 | 2017-06-22 | Olon Spa | Forme cristalline e amorfe di olaparib |
| WO2017188350A1 (ja) | 2016-04-28 | 2017-11-02 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 腫瘍の成長を抑制する方法 |
| CN109475524A (zh) | 2016-06-06 | 2019-03-15 | 万春药业公司 | 用于减少中性粒细胞减少症的组合物和方法 |
| HRP20240136T1 (hr) | 2016-06-29 | 2024-04-12 | Tesaro, Inc. | Metode liječenja raka jajnika |
| WO2018129381A1 (en) | 2017-01-06 | 2018-07-12 | Beyondspring Pharmaceuticals, Inc. | Tubulin binding compounds and therapeutic use thereof |
| KR20190109479A (ko) | 2017-02-01 | 2019-09-25 | 비욘드스프링 파마수티컬스, 인코포레이티드. | 호중구감소증의 감소 방법 |
| CA3052330A1 (en) * | 2017-02-06 | 2018-08-09 | City Of Hope | Treatment of cancer |
| AU2018246214B2 (en) | 2017-03-27 | 2021-07-08 | Merck Sharp & Dohme Llc | Niraparib compositions |
| TW202444417A (zh) | 2017-05-09 | 2024-11-16 | 美商提薩羅有限公司 | 治療癌症的組合療法 |
| CN110913911A (zh) | 2017-05-18 | 2020-03-24 | 特沙诺有限公司 | 用于治疗癌症的组合疗法 |
| CN107098862A (zh) * | 2017-06-05 | 2017-08-29 | 山东裕欣药业有限公司 | 一种奥拉帕尼二水合物及其制备方法 |
| CN111278433A (zh) * | 2017-09-26 | 2020-06-12 | 特沙诺有限公司 | 尼拉帕尼制剂 |
| WO2019067978A1 (en) | 2017-09-30 | 2019-04-04 | Tesaro, Inc. | POLYTHERAPIES FOR THE TREATMENT OF CANCER |
| US11801240B2 (en) | 2017-10-06 | 2023-10-31 | Tesaro, Inc. | Combination therapies and uses thereof |
| EP3713565A1 (en) | 2017-11-20 | 2020-09-30 | Basilea Pharmaceutica International AG | Pharmaceutical combinations for use in the treatment of neoplastic diseases |
| BR112020015909A2 (pt) * | 2018-02-05 | 2020-12-15 | Tesaro, Inc. | Formulações pediátricas de niraparib e métodos de tratamento pediátrico |
| JP2021522848A (ja) * | 2018-05-15 | 2021-09-02 | オンコロジー ベンチャー アーペーエス | 癌患者における薬物応答性を予測する方法 |
| CA3125197A1 (en) * | 2019-01-04 | 2020-07-09 | Actinium Pharmaceuticals, Inc. | Methods for treating cancer using combinations of parp inhibitors and antibody radioconjugates |
| US11083705B2 (en) | 2019-07-26 | 2021-08-10 | Eisai R&D Management Co., Ltd. | Pharmaceutical composition for treating tumor |
| ES3075649T3 (en) | 2019-07-26 | 2026-08-06 | Eisai R&D Man Co Ltd | Pharmaceutical composition for treating tumor |
| TW202228693A (zh) * | 2020-10-08 | 2022-08-01 | 瑞典商阿斯特捷利康公司 | 用於治療癌症之組合療法 |
| US20240197730A1 (en) * | 2021-04-09 | 2024-06-20 | Cardiff Oncology, Inc. | Cancer treatment using parp inhibitors and plk1 inhibitors |
| EP4319751A4 (en) | 2021-04-09 | 2025-02-26 | Beyondspring Pharmaceuticals, Inc. | THERAPEUTIC COMPOSITIONS AND METHODS FOR THE TREATING OF TUMORS |
| WO2024054898A1 (en) * | 2022-09-08 | 2024-03-14 | Cardiff Oncology, Inc. | Onvansertib and parp inhibitor combination |
| EP4583983A4 (en) | 2022-09-11 | 2026-07-15 | Cardiff Oncology Inc | PLK1 INHIBITOR IN COMBINATION WITH ANTI-ANGIOGENICS FOR THE TREATMENT OF METASTATIC CANCER |
| WO2024137738A1 (en) * | 2022-12-22 | 2024-06-27 | The Board Of Regents Of The University Of Oklahoma | Combinations of poly (adp-ribose) polymerase (parp) inhibitors and heteroarotinoids and methods of use as cancer treatments |
| JP2026509292A (ja) * | 2023-03-10 | 2026-03-17 | ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド | 腫瘍学的併用療法及びその使用方法 |
| WO2025106586A1 (en) * | 2023-11-13 | 2025-05-22 | Luxvitae Therapeutics Inc. | Macrocyclic ketone compounds and applications thereof |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6653341B1 (en) * | 1998-06-17 | 2003-11-25 | Eisai Co., Ltd. | Methods and compositions for use in treating cancer |
| SI2209375T1 (sl) * | 2007-10-03 | 2014-12-31 | Eisai Inc. | Spojine inhibitorja PARP in metode uporabe |
| EP2686441B1 (en) | 2011-03-18 | 2019-05-08 | Eisai R&D Management Co., Ltd. | Methods and uses for predicting response to eribulin |
| US9517229B2 (en) | 2011-07-29 | 2016-12-13 | Medivation Prostate Therapeutics, Inc. | Treatment of breast cancer |
-
2015
- 2015-05-28 JP JP2016569606A patent/JP6648040B2/ja active Active
- 2015-05-28 WO PCT/US2015/032990 patent/WO2015184145A1/en not_active Ceased
- 2015-05-28 EP EP15799685.1A patent/EP3148336B1/en active Active
- 2015-05-28 US US15/314,200 patent/US10238630B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3148336B1 (en) | Eribulin and poly (adp ribose) polymerase (parp) inhibitors as combination therapy for the treatment of cancer | |
| TWI361689B (en) | Substituted 2-alkyl quinazolinone derivatives as parp inhibitors | |
| JP2020516693A5 (enExample) | ||
| JP5551589B2 (ja) | ７−（２，５−ジヒドロ−４−イミダゾ［１，２−ａ］ピリジン−３−イル−２，５−ジオキソ−１Ｈ−ピロロ−３−イル）−９−フルオロ−１，２，３，４−テトラヒドロ−２−（１−ピペリジニル−カルボニル）ピロロ［３，２，１−ｊｋ］［１，４］ベンゾジアゼピンによる癌化学療法の相乗作用 | |
| EP3969050A1 (en) | Anti-cancer nuclear hormone receptor-targeting compounds | |
| TW200932239A (en) | PARP inhibitor compounds, compositions and methods of use | |
| ES2913097T3 (es) | Uso de derivados de quinolina para el tratamiento del cáncer de esófago y método de tratamiento, composición farmacéutica y equipo de los mismos | |
| CN103458896A (zh) | 用于治疗癌症的方法 | |
| KR20180129917A (ko) | 암 치료에 사용하기 위한 Notch 및 PI3K/mTOR 억제제의 조합 요법 | |
| CN105120663A (zh) | 用于利用羧胺三唑乳清酸盐治疗对先前化学治疗药物和靶向药物具有获得性耐药性的癌症的方法和组合物 | |
| JP2013511526A5 (enExample) | ||
| JP2019501962A5 (enExample) | ||
| CN101484443A (zh) | 放射线治疗增强剂 | |
| Goldman et al. | MA07. 05 phase 1b/2 study of combined HER inhibition in refractory EGFR-mutated metastatic non-small cell lung cancer (NSCLC) | |
| Han et al. | Effect of combination of rapamycin and cisplatin on human cervical carcinoma Hela cells | |
| Fecher et al. | Effectively targeting BRAF in melanoma: a formidable challenge. | |
| CN101155600A (zh) | 放射线治疗增强剂 | |
| CN102105147B (zh) | 包含aurora激酶抑制剂和抗肿瘤药的治疗组合 | |
| Cao et al. | Poly (ADP-Ribosyl) polymerase 1 inhibitors: A patent review | |
| CN111777621B (zh) | 喹唑啉衍生物类酪氨酸激酶抑制剂的新用途 | |
| CA3010654C (en) | Use of quinoline derivatives for treating oesophageal cancer and treatment method, pharmaceutical composition and kit thereof | |
| CN118019537A (zh) | Shp2抑制剂联合egfr-tki治疗和预防肿瘤疾病的医药用途 | |
| TW202508573A (zh) | 用於治療癌症之組合療法 | |
| WO2025212165A1 (en) | Targeted heterobifunctional small molecule proteolysis targeting chimeras | |
| WO2025250569A1 (en) | Cancer treatments using mta-cooperative prmt5 inhibitors and mat2a inhibitors |